Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 2/2018

01-03-2018 | Original Article

Therapeutic effect of icariin combined with stem cells on postmenopausal osteoporosis in rats

Authors: Dao Tang, Cuiling Ju, Yanjie Liu, Fei Xu, Zhengguang Wang, Dongbo Wang

Published in: Journal of Bone and Mineral Metabolism | Issue 2/2018

Login to get access

Abstract

Osteoporosis is characterized by skeletal fragility and microarchitectural deterioration. The side effects of drugs to treat osteoporosis will negatively affect the health of patients. This study aimed to investigate the therapeutic effects of icariin combined with adipose-derived stem cells on osteoporosis in a postmenopausal osteoporosis model after ovariectomy in rats. After ovariectomy the rats were treated with icariin combined with adipose-derived stem cell transplantation. The levels of alkaline phosphatase, tartrate-resistant acid phosphatase, osteoprotegerin, and bone γ-carboxyglutamate protein in serum were determined by ELISA. The bone mineral density was measured by dual-energy X-ray absorptiometry. The mechanical properties were determined by a three-point bending test. The kidney functions were evaluated by an automatic analyzer and a diagnostic kit. Icariin combined with stem cells significantly reduced body weight gain caused by ovariectomy, significantly decreased alkaline phosphatase, tartrate-resistant acid phosphatase, and bone γ-carboxyglutamate protein content in serum, significantly increased osteoprotegerin content, significantly elevated bone mineral density of the lumbar spine, left femur, and right femur, and enhanced bone biomechanical properties of the femur, including maximum bending load, bending rigidity, and fracture energy, in osteoporotic rats. In addition, icariin combined with stem cells substantially decreased the damage to the liver and kidney in osteoporotic rats. Icariin combined with stem cells can not only ameliorate reduction of bone mass and disruption of the microarchitectural structure of bone tissue caused by osteoporosis in a rat model but can also have a beneficial effect on organ functions, such as those of the liver and kidney.
Literature
1.
go back to reference Lindsay R (1993) Pathogenesis of postmenopausal osteoporosis. Baillieres Clin Rheumatol 7:499–513CrossRef Lindsay R (1993) Pathogenesis of postmenopausal osteoporosis. Baillieres Clin Rheumatol 7:499–513CrossRef
2.
go back to reference Edwards BJ, Brooks ER, Langman CB (2004) Osteoporosis screening of postmenopausal women in the primary care setting: a case-based approach. Gend Med 1:70–85CrossRef Edwards BJ, Brooks ER, Langman CB (2004) Osteoporosis screening of postmenopausal women in the primary care setting: a case-based approach. Gend Med 1:70–85CrossRef
3.
go back to reference Meeta Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S (2013) Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations. J Midlife Health 4:107–126PubMedPubMedCentral Meeta Harinarayan CV, Marwah R, Sahay R, Kalra S, Babhulkar S (2013) Clinical practice guidelines on postmenopausal osteoporosis: an executive summary and recommendations. J Midlife Health 4:107–126PubMedPubMedCentral
4.
go back to reference Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368–381CrossRef Kanis JA (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int 4:368–381CrossRef
5.
go back to reference Leung PC, Siu WS (2013) Herbal treatment for osteoporosis: a current review. J Tradit Complement Med 3:82–87CrossRef Leung PC, Siu WS (2013) Herbal treatment for osteoporosis: a current review. J Tradit Complement Med 3:82–87CrossRef
6.
go back to reference Hinton PS, Nigh P, Thyfault J (2015) Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: a 12-month randomized, clinical trial. Bone 79:203–212CrossRef Hinton PS, Nigh P, Thyfault J (2015) Effectiveness of resistance training or jumping-exercise to increase bone mineral density in men with low bone mass: a 12-month randomized, clinical trial. Bone 79:203–212CrossRef
7.
go back to reference Evans RK, Negus CH, Centi AJ, Spiering BA, Kraemer WJ, Nindl BC (2012) Peripheral QCT sector analysis reveals early exercise induced increases in tibial bone mineral density. J Musculoskelet Neuronal Interact 12:155–164PubMed Evans RK, Negus CH, Centi AJ, Spiering BA, Kraemer WJ, Nindl BC (2012) Peripheral QCT sector analysis reveals early exercise induced increases in tibial bone mineral density. J Musculoskelet Neuronal Interact 12:155–164PubMed
8.
go back to reference Bauer DC (2013) Calcium supplements and fracture prevention. N Engl J Med 369:1537–1543CrossRef Bauer DC (2013) Calcium supplements and fracture prevention. N Engl J Med 369:1537–1543CrossRef
9.
go back to reference Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683CrossRef Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J et al (2006) Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354:669–683CrossRef
10.
go back to reference Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta analysis. J Clin Endocrinol Metab 97:1871–1880CrossRef Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta analysis. J Clin Endocrinol Metab 97:1871–1880CrossRef
11.
go back to reference Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738CrossRef Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, LeBoff M, Lewis CE, McGowan J, Neuner J, Pettinger M, Stefanick ML, Wactawski-Wende J, Watts NB (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women’s Health Initiative randomized trial. JAMA 290:1729–1738CrossRef
12.
go back to reference Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711–723CrossRef Crandall CJ, Newberry SJ, Diamant A, Lim YW, Gellad WF, Booth MJ, Motala A, Shekelle PG (2014) Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review. Ann Intern Med 161:711–723CrossRef
13.
go back to reference Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRef Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765CrossRef
14.
go back to reference Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRef Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRef
15.
go back to reference Qin L, Zhang G, Hung WY, Shi Y, Leung K, Yeung HY, Leung P (2005) Phytoestrogen rich herb formula “XLGB” prevent OVX-induced deterioration of musculoskeletal tissues. J Bone Miner Metab 23:55–61CrossRef Qin L, Zhang G, Hung WY, Shi Y, Leung K, Yeung HY, Leung P (2005) Phytoestrogen rich herb formula “XLGB” prevent OVX-induced deterioration of musculoskeletal tissues. J Bone Miner Metab 23:55–61CrossRef
16.
go back to reference Zhang Y, Lai WP, Wong MS (2006) Effects of Fracutus Ligustri Lucidi extract on bone turn over and calcium balance in ovariectomized rats. Biot Pharm Bull 29:291–296CrossRef Zhang Y, Lai WP, Wong MS (2006) Effects of Fracutus Ligustri Lucidi extract on bone turn over and calcium balance in ovariectomized rats. Biot Pharm Bull 29:291–296CrossRef
17.
go back to reference Li GW, Xu Z, Chang SX, Nian H, Wang XY, Qin LD (2014) Icariin prevents ovariectomy-induced bone loss and lowers marrow adipogenesis. Menopause 21:1007–1016CrossRef Li GW, Xu Z, Chang SX, Nian H, Wang XY, Qin LD (2014) Icariin prevents ovariectomy-induced bone loss and lowers marrow adipogenesis. Menopause 21:1007–1016CrossRef
18.
go back to reference Mao XY, Bian Q, Shen ZY (2012) Analysis of the osteogenetic effects exerted on mesenchymal stem cell strain C3H10T1/2 by icariin via MAPK signaling pathway in vitro. Zhong Xi Yi Jie He Xue Bao 10:1272–1278CrossRef Mao XY, Bian Q, Shen ZY (2012) Analysis of the osteogenetic effects exerted on mesenchymal stem cell strain C3H10T1/2 by icariin via MAPK signaling pathway in vitro. Zhong Xi Yi Jie He Xue Bao 10:1272–1278CrossRef
19.
go back to reference Levis S, Theodore GJ (2012) Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. Manag Care Pharm 18:S1–15CrossRef Levis S, Theodore GJ (2012) Summary of AHRQ’s comparative effectiveness review of treatment to prevent fractures in men and women with low bone density or osteoporosis: update of the 2007 report. Manag Care Pharm 18:S1–15CrossRef
20.
21.
go back to reference Kapoor S (2013) Icariin and its emerging role in the treatment osteoporosis. Chin Med J (Engl) 126:400 Kapoor S (2013) Icariin and its emerging role in the treatment osteoporosis. Chin Med J (Engl) 126:400
22.
go back to reference Liu M, Zhong C, He RX, Chen LF (2012) Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis. Chin Med J (Engl) 125:1784–1789 Liu M, Zhong C, He RX, Chen LF (2012) Icariin associated with exercise therapy is an effective treatment for postmenopausal osteoporosis. Chin Med J (Engl) 125:1784–1789
23.
go back to reference Zhang G, Qin L, Shi Y (2007) Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double- blind and placebo-controlled trial. J Bone Miner Res 22:1072–1079CrossRef Zhang G, Qin L, Shi Y (2007) Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double- blind and placebo-controlled trial. J Bone Miner Res 22:1072–1079CrossRef
24.
go back to reference Caplan AI (2015) Adult mesenchymal stem cells and women’s health. Menopause 22:131–135CrossRef Caplan AI (2015) Adult mesenchymal stem cells and women’s health. Menopause 22:131–135CrossRef
25.
go back to reference Kwak EJ, Lee YS, Choi EM (2012) Effect of magnolol on the function of osteoblastic MC3T3-E1 cells. Mediat Inflamm 2012:829650CrossRef Kwak EJ, Lee YS, Choi EM (2012) Effect of magnolol on the function of osteoblastic MC3T3-E1 cells. Mediat Inflamm 2012:829650CrossRef
26.
go back to reference Eastell R, Reid DM, Vukicevic S, Ensrud KE, LaCroix AZ, Thompson JR, Thompson DD, Cummings SR (2012) Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone 50:1135–1140CrossRef Eastell R, Reid DM, Vukicevic S, Ensrud KE, LaCroix AZ, Thompson JR, Thompson DD, Cummings SR (2012) Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone 50:1135–1140CrossRef
27.
go back to reference Mok SK, Chen WF, Lai WP, Leung PC, Wang XL, Yao XS, Wong MS (2010) Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol 159:939–949CrossRef Mok SK, Chen WF, Lai WP, Leung PC, Wang XL, Yao XS, Wong MS (2010) Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells. Br J Pharmacol 159:939–949CrossRef
Metadata
Title
Therapeutic effect of icariin combined with stem cells on postmenopausal osteoporosis in rats
Authors
Dao Tang
Cuiling Ju
Yanjie Liu
Fei Xu
Zhengguang Wang
Dongbo Wang
Publication date
01-03-2018
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 2/2018
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-017-0831-x

Other articles of this Issue 2/2018

Journal of Bone and Mineral Metabolism 2/2018 Go to the issue